search
Back to results

Clobazam in Subjects With Lennox-Gastaut Syndrome

Primary Purpose

Epilepsy, Epilepsy, Generalized, Seizures

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Clobazam Low Dose
Clobazam High Dose
Sponsored by
Lundbeck LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Epilepsy

Eligibility Criteria

2 Years - 30 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria: Subject must have been <11 years of age at the onset of LGS Subject must have LGS Subject must be on at least 1 stable dose AED Parent or caregiver must be able to keep an accurate seizure diary Key Exclusion Criteria: Etiology of subject's seizures is a progressive neurologic disease. Subjects with tuberous sclerosis will not be excluded from study participation Subject has had an episode of status epilepticus within 12 weeks of baseline Subject has had an anoxic episode requiring resuscitation within 1 year of screening Subject has had a clinically significant history of an allergic reaction or significant sensitivity to benzodiazepines Subject is taking more than 3 concurrent AEDs. Note: Vagal Nerve Stimulation (VNS) or ketogenic diet is allowed and each will be counted as one of the three allowed AEDs If the subject is on the ketogenic diet, has been for less than 4 weeks prior to screening or suffers from frequent stooling If the subject has a VNS, the settings have not been stable for at least 4 weeks prior to screening Subject has taken corticotropins in the 6 months prior to screening Subject is currently taking long-term systemic steroids (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception will be made of prophylactic medication, for example, for urinary tract infections or asthma If the subject is taking felbamate, has been taking it for less than 1 year prior to screening or previous treatment with felbamate resulted in withdrawal due to liver or bone marrow adverse events

Sites / Locations

  • Barrow Neurological Institute
  • Childrens Hospital Los Angeles
  • Children's National Medical Center
  • Pediatric Epilepsy & Neurology Specialists
  • Massachusetts General Hospital
  • Childrens Hospital Boston
  • Minnesota Epilepsy Group, P.A.
  • Children's Hospital
  • University of Tennessee Health Science Center
  • Dallas Pediatric Neurology Associates
  • Texas Child Neurology, LLP
  • Monarch Medical Research
  • Virginia Commonwealth University
  • Children's Hospital of Wisconsin

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Clobazam Low Dose

Clobazam High Dose

Arm Description

Outcomes

Primary Outcome Measures

Percent Reduction in Number of Drop Seizures.
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.
A Comparison of the High Dose Group to Low Dose Group of the Percent Reduction in Number of Drop Seizures.
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.

Secondary Outcome Measures

Percent of Patients Considered Treatment Responders Defined as Those With a >= 25%, >= 50%, >= 75%, and 100% Reduction in Drop Seizures.
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.
Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms.
The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms.
The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".

Full Information

First Posted
September 9, 2005
Last Updated
January 6, 2012
Sponsor
Lundbeck LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00162981
Brief Title
Clobazam in Subjects With Lennox-Gastaut Syndrome
Official Title
Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
October 2005 (undefined)
Primary Completion Date
August 2006 (Actual)
Study Completion Date
October 2006 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lundbeck LLC

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in subjects 2 to 30 years of age with Lennox-Gastaut Syndrome (LGS). Subjects will be enrolled at approximately 10 investigational sites in the U.S. for up to 15 weeks. Subjects will be randomly assigned to either a low dose or a high dose. The study will include a baseline period, a titration period and a maintenance period. After the maintenance period, subjects will either continue into an open-label extension study or enter the taper period with a final visit 1 week after the last dose.
Detailed Description
LGS poses a significant treatment challenge. While antiepileptic medications are the mainstay of treatment, no one antiepileptic drug (AED) provides satisfactory relief for all or most patients with LGS and a combination of treatments is often required. Many patients with LGS are refractory to standard AED treatment. More effective and better tolerated treatment options are needed for this population of medically intractable epilepsy patients. Clobazam is unique in that it is the only non-1, 4-benzodiazepine used in the treatment of epilepsy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy, Epilepsy, Generalized, Seizures

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
68 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Clobazam Low Dose
Arm Type
Experimental
Arm Title
Clobazam High Dose
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Clobazam Low Dose
Other Intervention Name(s)
Onfi™
Intervention Description
5 to 10 mg/day with doses in the morning and at bedtime; orally
Intervention Type
Drug
Intervention Name(s)
Clobazam High Dose
Other Intervention Name(s)
Onfi™
Intervention Description
5 to 40 mg/day with doses in the morning and at bedtime; orally
Primary Outcome Measure Information:
Title
Percent Reduction in Number of Drop Seizures.
Description
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.
Time Frame
4-week baseline period and 4-week maintenance period
Title
A Comparison of the High Dose Group to Low Dose Group of the Percent Reduction in Number of Drop Seizures.
Description
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.
Time Frame
4-week baseline period and the 4-week maintenance period
Secondary Outcome Measure Information:
Title
Percent of Patients Considered Treatment Responders Defined as Those With a >= 25%, >= 50%, >= 75%, and 100% Reduction in Drop Seizures.
Description
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.
Time Frame
4-week baseline period and 4-week maintenance period
Title
Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms.
Description
The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
Time Frame
Week 3
Title
Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms.
Description
The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
Time Frame
Week 7

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Subject must have been <11 years of age at the onset of LGS Subject must have LGS Subject must be on at least 1 stable dose AED Parent or caregiver must be able to keep an accurate seizure diary Key Exclusion Criteria: Etiology of subject's seizures is a progressive neurologic disease. Subjects with tuberous sclerosis will not be excluded from study participation Subject has had an episode of status epilepticus within 12 weeks of baseline Subject has had an anoxic episode requiring resuscitation within 1 year of screening Subject has had a clinically significant history of an allergic reaction or significant sensitivity to benzodiazepines Subject is taking more than 3 concurrent AEDs. Note: Vagal Nerve Stimulation (VNS) or ketogenic diet is allowed and each will be counted as one of the three allowed AEDs If the subject is on the ketogenic diet, has been for less than 4 weeks prior to screening or suffers from frequent stooling If the subject has a VNS, the settings have not been stable for at least 4 weeks prior to screening Subject has taken corticotropins in the 6 months prior to screening Subject is currently taking long-term systemic steroids (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception will be made of prophylactic medication, for example, for urinary tract infections or asthma If the subject is taking felbamate, has been taking it for less than 1 year prior to screening or previous treatment with felbamate resulted in withdrawal due to liver or bone marrow adverse events
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Email contact via H. Lundbeck A/S
Organizational Affiliation
LundbeckClinicalTrials@lundbeck.com
Official's Role
Study Director
Facility Information:
Facility Name
Barrow Neurological Institute
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
Facility Name
Childrens Hospital Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Facility Name
Children's National Medical Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Facility Name
Pediatric Epilepsy & Neurology Specialists
City
Tampa
State/Province
Florida
ZIP/Postal Code
33609
Country
United States
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Childrens Hospital Boston
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Minnesota Epilepsy Group, P.A.
City
St. Paul
State/Province
Minnesota
ZIP/Postal Code
55102
Country
United States
Facility Name
Children's Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States
Facility Name
University of Tennessee Health Science Center
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38105
Country
United States
Facility Name
Dallas Pediatric Neurology Associates
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Texas Child Neurology, LLP
City
Plano
State/Province
Texas
ZIP/Postal Code
75075
Country
United States
Facility Name
Monarch Medical Research
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23510
Country
United States
Facility Name
Virginia Commonwealth University
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Facility Name
Children's Hospital of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53201
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
19170737
Citation
Conry JA, Ng YT, Paolicchi JM, Kernitsky L, Mitchell WG, Ritter FJ, Collins SD, Tracy K, Kormany WN, Abdulnabi R, Riley B, Stolle J. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009 May;50(5):1158-66. doi: 10.1111/j.1528-1167.2008.01935.x. Epub 2008 Dec 15.
Results Reference
background

Learn more about this trial

Clobazam in Subjects With Lennox-Gastaut Syndrome

We'll reach out to this number within 24 hrs